Elaia is an independent venture capital firm, focused on the digital economy and deep tech. With over €700m under management, Elaia invests in high-potential disruptive startups from the first financing rounds to the emergence of global leaders. With more than 75 years of cumulated experience in both venture capital and digital industries, the investment team offers close, proactive, and relevant support to its entrepreneurs. Elaia was founded in 2002 by Philippe Gire and Xavier Lazarus and is based in Paris, Ile-de-France, France.

Elaia

Credit Agricole is a universal banking corporation active with focuses on corporate and investment banking, retail banking, insurance, consumer finance and savings management. Crédit Agricole Group is serving 54 million customers (Individuals, farmers, small businesses, local authorities, institutions, corporates) across 46 countries Crédit Agricole is : - Number 1 provider of financing to the French economy (Internal source: ECO 2023) - Number 1 European asset manager with its subsidiary Amundi (Source: IPE “Top 500 Asset Managers”, June 2023) - Number 1 insurer in France (Source: L’Argus de l’assurance, 13 December 2023 - data at end-2022) - Number 1 retail bank in the European Union based on number of customers - 9th largest global bank by balance sheet size (Source: The Banker 2024) Crédit Agricole Group supports its customers in their plans and projects in France and around the world, through its operations in all segments of the market including insurance, real estate, payment systems, asset management, leasing and factoring, consumer finance, and corporate and investment banking.  Crédit Agricole also stands out for its dynamic, innovative corporate social responsibility policy serving the economy. This policy is based on a pragmatic approach that permeates throughout the entire Group and engages all its employees. Its recent inclusion in the Vigeo-NYSE Euronext extra-financial indices is recognition of this engagement.

Crédit Agricole

Pertinence Invest is an investment Firm that works with tech start ups.

Pertinence Invest

Fournier-Majoie Foundation is a non-profit organization whose mission is to identify, support and guide promising researchers.

Fournier-Majoie

Sham is a mutual insurance company that provides medical malpractice insurance in France.

Sham

Simba Santé seeks to invest in the healthcare and medical devices sector.

Simba Santé

Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage. The firm manages over €2 billion of assets dedicated to life science investing and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact its collective future. It invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations with a focus on Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. They sit on the boards of their portfolio companies and play an active role from the formation phase alongside entrepreneurs. It was headquartered in Paris, Ile-de-France in 1972.

Sofinnova Partners

Mérieux Equity Partners (“MxEP”) is a management company dedicated to venture, growth and LBO investments in the healthcare and nutrition sectors. MxEP actively supports entrepreneurs and industrial companies with differentiated products and services, by providing privileged access to its expertise and international network. MxEP currently manages more than €600m AUM and has recently launched a new vehicle MP3 of €350m dedicated to growth/LBO.

Mérieux Equity Partners

Mablink Bioscience

Mablink Bioscience is a biotechnology company specialized in the development of a new class of cancer drugs, called Antibody Drug Conjugate (ADC).

Mablink Bioscience is a biotechnology company developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. Its proprietary PSARLink technology involves linking antibodies to cytotoxic payloads via a unique hydrophilic linker structure. This "masking" approach enables the ADCs to remain stable in the plasma and stay longer in the body, allowing more time to target and kill tumor cells. Notably, PSARLink ADCs have demonstrated an improved therapeutic index of up to 10-fold in animal models compared to conventional ADCs, potentially offering a broader therapeutic window.

Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023

Mablink Bioscience receives €31M series A funding for ADC pipeline

Mablink Bioscience Enters an Agreement to be Acquired by Lilly

Mablink Bioscience Announces a €31 Million Series A Funding Round Led by Sofinnova Partners and Mérieux Equity Partners

Mablink Bioscience enters an agreement to be acquired by Lilly — Sofinnova Partners

Mablink Bioscience announces appointment of its Chief Development Officer

Mablink Bioscience announces a €31 million Series A funding round led by Sofinnova Partners and Mérieux Equity Partners — Sofinnova Partners

MABLINK BIOSCIENCES

Targeting complex diseases with complex molecules

Large-molecule Therapeutics

Eli Lilly is buying another European cancer firm Mablink Bioscience

Mablink Bioscience is a biotechnology company developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. Its proprietary PSARLink technology involves linking antibodies to cytotoxic payloads via a unique hydrophilic linker structure. This "masking" approach enables the ADCs to remain stable in the plasma and stay longer in the body, allowing more time to target and kill tumor cells. Notably, PSARLink ADCs have demonstrated an improved therapeutic index of up to 10-fold in animal models compared to conventional ADCs, potentially offering a broader therapeutic window.
Mablink's lead candidate, MBK-103, is an ADC targeting the folate receptor alpha (FRα) overexpressed in several solid tumors. It consists of an Fc-attenuated humanized IgG1 antibody, the PSARLink linker, and the potent topoisomerase I inhibitor exatecan as the payload. preclinical studies revealed significant tumor growth inhibition across multiple FRα-positive mouse models at low doses of 1-3 mg/kg. Additionally, MBK-103 exhibited promising safety results in non-human primates, enabling a broad therapeutic window. Mablink plans to submit an IND for MBK-103 in the fourth quarter of 2023, following successful manufacturing process development.
In October 2023, Mablink entered an agreement to be acquired by Eli Lilly and Company, reflecting the potential of its existing pipeline and PSARLink technology for developing additional drug conjugates. The acquisition is subject to approval from the French Ministry of the Economy.

Innovent Biologics is a leading biopharmaceutical company founded in 2011 with the mission to develop and commercialize innovative and affordable medicines. The company focuses on oncology, cardiovascular and metabolic diseases, autoimmune disorders, and ophthalmology. As of March 2024, Innovent has ten approved products in the Chinese market, including TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), and others. The company's core product, TYVYT, is an anti-PD-1 monoclonal antibody approved across seven indications, making it the most widely approved PD-1 inhibitor in China.
Innovent has a robust pipeline with three new drug applications under review, four assets in Phase III or pivotal trials, and 19 molecules in early clinical development. The company's innovative pipeline spans various modalities, including bispecific antibodies, antibody-drug conjugates (ADCs), and RNA therapeutics. In oncology, Innovent is advancing the next-generation immunotherapy combinations with ADCs, such as the CLDN18.2 ADC (IBI343) and the EGFR/B7H3 bispecific ADC (IBI3001). The company's metabolic pipeline includes mazdutide, a first-in-class GLP-1R/GCGR dual agonist in late-stage development for weight management.
Innovent has a strong emphasis on global innovation, with its Innovent Academy delivering eight novel molecules into IND-enabling stage in 2023. The company has established large-scale manufacturing facilities in Suzhou and Hangzhou to support global supply. Innovent collaborates with over 30 global healthcare leaders, reinforcing its commitment to advancing biopharmaceutical innovation worldwide.

Innovent Biologics

<div>
 
 ADC Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing next-generation antibody-drug conjugates (ADCs) for treating cancer. The company's ADCs leverage highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology, which causes the ADCs' antibodies to bind to specific tumor cell surface antigens. Once internalized, the potent PBD dimer is released inside the cell, creating covalent cross-links between the DNA strands, disrupting cell division without triggering DNA repair mechanisms.
 
 
 
 
 ADC Therapeutics' lead product candidate, Zynlonta, received FDA approval in April 2021 for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. The company is also advancing a deep pipeline of other PBD-based ADCs targeting hematologic malignancies and solid tumors. As of May 2021, ADC Therapeutics reported revenues of USD 38.2 million, reflecting initial sales of Zynlonta.
 
 
 
 
 In March 2022, ADC Therapeutics acquired US commercial rights to Overrkey Biological's anti-HER2 ADC Overena, broadening its cancer treatment portfolio. The acquisition aligned with the company's strategic focus on expanding globally with its PBD-based ADC technology.
 
</div>

ADC Therapeutics

Sirnaomics is a biopharmaceutical company engaged in the discovery and development of RNA therapeutics. The company focuses on innovative drugs for indications with unmet medical needs and large market opportunities. Sirnaomics utilizes two proprietary delivery platforms: the Polypeptide Nanoparticle Formulation (PNP) and the second generation of GalNAc conjugates called GalAhead.
Sirnaomics has established a robust pipeline of drug candidates, with several products in clinical and preclinical stages. The company's lead clinical product, STP705, has demonstrated positive results in Phase II clinical trials for the treatment of squamous cell carcinoma in situ (isSCC) and basal cell carcinoma (BCC). Additionally, STP705 is being explored for focal fat reduction in the medical aesthetics field. Another promising candidate, STP707, is a PNP formulation consisting of two siRNAs targeting TGF-β1 and COX-2 for intravenous treatment of solid tumors. STP707 has shown promising results in a Phase I basket clinical study, exhibiting stable disease response in 74% of evaluable patients.
Sirnaomics achieved a significant milestone by advancing STP122G, the first candidate utilizing the GalAhead technology, into clinical development. STP122G targets Factor XI for anticoagulation therapeutics and is currently undergoing Phase I clinical trials.
In March 2023, Sirnaomics' subsidiary, RNAimmune, received IND clearance from the FDA to initiate a Phase I clinical trial for RV-1770, an mRNA vaccine targeting respiratory syncytial virus (RSV). Additionally, RNAimmune obtained FDA clearance for a SARS-CoV-2 vaccine booster candidate, RV-1730.
Sirnaomics has established its manufacturing facility in China, enabling the transition from a biotech company to a biopharmaceutical corporation. The facility has successfully produced a full GMP batch of STP707 for human injection and is expected to support the company's clinical pipeline.
In July 2024, Sirnaomics announced the completion of IND-enabling studies for STP125G, an siRNA therapeutic targeting Apolipoprotein C3 (ApoC3) for the treatment of cardiovascular diseases. The positive results from non-human primate studies support the filing of an IND with the FDA.

Sirnaomics

Sesen Bio is a late-stage clinical company that previously focused on developing targeted fusion protein therapeutics for cancer treatment. Its lead product candidate, Vicineum, is a locally administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive bladder cancer (NMIBC).
In February 2021, the FDA accepted Sesen Bio's Biologics License Application (BLA) for Vicineum to treat BCG-unresponsive NMIBC, granting Priority Review. However, in August 2021, the company received a Complete Response Letter from the FDA, requiring an additional Phase 3 clinical trial for potential resubmission. Following discussions with the FDA in March 2022, Sesen Bio aligned on most elements for the trial design and planned to meet again in mid-2022 to finalize outstanding items.
On July 15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development of Vicineum in the US due to the incremental timeline and costs associated with the additional Phase 3 trial. The company shifted its primary focus to consummating a strategic transaction to maximize shareholder value while seeking a partner for Vicineum's further development.
In September 2022, Sesen Bio announced a pending merger with Carisma Therapeutics, a clinical-stage biopharmaceutical company developing immunotherapies based on engineered macrophages. This merger was approved by Sesen Bio's stockholders in March 2023, with the combined company operating under the name Carisma Therapeutics Inc. and trading on the Nasdaq under the ticker "CARM".
Upon closing the merger in March 2023, Sesen Bio declared a special cash dividend of USD 75 million (around USD 0.36 per share) to its stockholders and issued them Contingent Value Rights (CVRs) entitling them to potential proceeds from the sale of Vicineum and other assets, as well as a USD 30 million milestone payment under the Roche Asset Purchase Agreement.

Sesen Bio

ACELYRIN, INC. is a late-stage clinical biopharmaceutical company focused on developing transformative medicines for immunology and inflammatory diseases. The company's lead product candidate is izokibep, a next-generation inhibitor of interleukin-17A (IL-17A) designed to overcome limitations of monoclonal antibodies. Izokibep is being evaluated in multiple late-stage trials for moderate-to-severe hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and noninfectious uveitis.
In March 2024, ACELYRIN reported positive top line data from a global Phase 2 billion/3 clinical trial of izokibep in PsA, meeting the primary endpoint of ACR50 at 16 weeks with high statistical significance. The trial also demonstrated robust clinical responses for higher hurdle endpoints like ACR70, PASI100, and composite measures, indicating izokibep's potential to provide clinically meaningful benefits. Additionally, ACELYRIN announced differentiated long-term 32-week data from a global Phase 2 billion trial of izokibep in HS, showing rapid, dose-ordered improvement across multiple disease manifestations, including HiSCR100 achieved earlier than reported by other IL-17 inhibitors.
ACELYRIN's other late-stage asset is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of thyroid eye disease (TED). In March 2024, ACELYRIN announced positive proof-of-concept data from a Phase 1/2 trial, demonstrating rapid improvements in proptosis and clinical activity score within three weeks after the first dose.
As of December 31, 2023, ACELYRIN had cash, cash equivalents, and short-term marketable securities totaling USD 721.3 million, providing a runway to support key late-stage data milestones and registrational studies across multiple indications. In January 2023, ACELYRIN acquired ValenzaBio, adding lonigutamab and other immunology assets to its pipeline.

ACELYRIN

Companies that develop engineered proteins that can target specific proteins or cells in the body

Companies that develop large molecules that can be used to target specific RNA molecules in the body, either to silence or replace them

Companies that develop large molecules that combine the targeting ability of monoclonal antibodies with the cytotoxic effects of chemotherapy drugs

Companies that develop large molecules that can be used to replace or supplement deficient or malfunctioning proteins in the body

Companies specializing in peptide-based treatments leverage short amino acid chains, known as peptides, to target and modulate various biological processes for therapeutic applications

AL/ML used to identify potential drug targets, and support protein engineering and optimization

Mablink Bioscience

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless